TxCell appoints Stéphane Boissel CEO
This article was originally published in Scrip
Executive Summary
Valbonne, France-based TxCell, a biotechnology company developing cost-effective, personalized T-cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, has named Stéphane Boissel CEO. Prior to joining TxCell, Mr Boissel was CEO of Genclis, a molecular diagnostic company. He succeeds Damian Marron, who has resigned from the company to pursue other interests.